PR94001

EAST RUTHERFORD, N.J., Jan. 11, 2022 /PRNewswire=KYODO JBN/ --

Cambrex recently celebrated the 40th anniversary of its founding in 1981.

Following forty years of growth and transformation into a leading global

contract development and manufacturing organization (CDMO), Cambrex continues

its commitment to leadership in pharmaceutical drug substance manufacturing

with over $100 million of investments in progress across its global

manufacturing network.

"As Cambrex celebrates our 40th anniversary, we are proud to be making

significant investments in capacity and new capabilities across our network,"

said Thomas Loewald, Cambrex CEO. He added, "Paired with our growing team of

over 2,200 employees; these investments will enable us to serve our customers

better as we partner with them in the development and manufacturing of novel,

life-changing therapies."

The largest of the expansions in Charles City, IA, is a $50 million project to

support the large-scale development and manufacturing of small molecule drug

substances. As the latest in a series of significant investments at the site,

the expansion will increase the facility's capacity by approximately 30 percent

with reactors sized up to 16,000 liters, ideal for efficient production of

large-volume commercial drug substances. The new capacity will come online

during the first half of 2022.

In October 2021, a further $30 million investment was announced at Cambrex's

High Point, NC facility focused on clinical-stage drug substance and

small-volume commercial manufacturing services. Now in progress, the expansion

will approximately double the facility's capacity by adding new chemistry

laboratories, new clinical manufacturing suites, and a small-scale commercial

manufacturing operation with reactors up to 2,000 liters. In addition to

expanding Cambrex's leadership in continuous flow chemistry, this investment

will give Cambrex the ability to develop and manufacture highly potent APIs for

its customers within a single facility. The High Point facility expansion will

be completed during the first half of 2023.

In Europe, Cambrex is midway through a series of upgrades at its Karlskoga,

Sweden facility totaling over $20 million, which will increase multi-purpose

capacity by 25 percent and provide more flexibility in API manufacturing. Less

than a year removed from installing a new 6,000-liter drug substance production

line, the site is now executing a similar project to add additional cGMP

manufacturing capacity by the end of 2022.

These investments, which span all scales of clinical and commercial drug

substance manufacturing, will ensure Cambrex continues to be well-positioned to

support its customers in the development and manufacturing of innovative new

therapies that improve human health.

About Cambrex

Cambrex is a leading global contract development and manufacturing organization

(CDMO) that provides drug substance, drug product, and analytical services

across the entire drug lifecycle. With over 40 years of experience and a

growing team of over 2,200 experts servicing global clients from North America

and European sites, Cambrex is a trusted partner in branded and generic markets

for API and dosage form development and manufacturing.

Cambrex offers a range of specialized drug substance technologies and

capabilities, including biocatalvsis. continuous flow, controlled substances,

solid-state science, material characterization, and highly potent APIs. In

addition, Cambrex can support conventional dosage forms, including oral solids,

semi-solids, and liquids, and has the expertise to manufacture specialty dosage

forms such as modified-release, fixed-dose combination, pediatric, bi-layer

tablets, stick packs, topicals, controlled substances, sterile and non-sterile

ointments.

For more information, visit www.cambrex.com 

Contact:          

Eli Cohen, Sr. Director of Marketing

Email: press@cambrex.com  

Phone: +1 919 544 8638

Logo - https://mma.prnewswire.com/media/1723116/Cambrex_40_Years_Logo.jpg

Source: Cambrex